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Abstract 
Background: Keratitis is a common cause of blindness. Current anti-inflammatory drugs used in keratitis have pro-
found side effects. Small peptides derived from endogenous proteins potentially display both desired efficiency and 
safety. We identified an 11-amino-acid peptide, H-RN, from hepatocyte growth factor (HGF), an endogenous protein 
with anti-inflammatory properties. We evaluated the effects of H-RN in keratitis in vitro and in vivo.
Methods: In vitro, corneal fibroblasts were stimulated with LPS or poly(I:C), surrogates for bacteria and viruses. 
Inflammatory cytokines, intercellular cell adhesion molecule-1 (ICAM-1), translocation of NF-κB p65, activation of IκBα, 
NF-κB, and MAPKs were detected. In vivo, keratitis in rats was induced by LPS. Clinical, histological observation, and 
quantification of cytokines in the cornea were conducted. H-RN safety was measured by cell viability, clinical, histo-
logical, and microstructural observations.
Results: H-RN inhibited IL-6, monocyte chemotactic protein-1(MCP-1), Interferon- γ(IFN-γ), and ICAM-1 expression 
triggered by LPS or poly(I:C), alleviated the clinical manifestation and reduced the clinical score in keratitis in vivo. 
The histological disorder and proinflammatory cytokines of the cornea were also reduced. The translocation of NF-κB 
and phosphorylation of IκBα, NF-κB, p38, JNK, and ERK were significantly inhibited by H-RN. No sign of toxicity was 
observed.
Conclusions: H-RN effectively attenuated keratitis in vivo and in vitro induced by LPS or poly(I:C) through blocking 
NF-κB and MAPK signaling pathways. It may be a promising and safe agent in treating keratitis.
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Background
Inflammatory corneal diseases could cause severe dam-
age to the physical structure and visual functions, lead-
ing to opacity, scarring, perforation of the cornea, and 
even permanent vision loss [1]. Bacteria and viruses are 
the most common infectious agents that affect the ocu-
lar surface and result in inflammatory damages. Once 
exposed to those insults, the immune system of the 
cornea is triggered, followed by the release of cytokines 
and infiltration of inflammatory cells [2, 3]. Even though 
antibiotics and antivirals eliminate many of the microbes, 
the inflammatory process initiated by the infection 
won’t stop immediately, causing lasting and recurrent 
destructive actions [4]. Anti-inflammatory or immu-
nosuppressive agents are needed to limit the immune 
response. However, such drug options are relatively lim-
ited and generate profound side effects, including glau-
coma, cataract, and delay of healing [5]. Identifying and 
developing new drugs which display both desired effi-
ciency and satisfactory safety is a challenge. Due to the 
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immunogenicity, higher penetration capability, and bet-
ter cost-effectiveness are preferred and display certain 
merits [5–7].
Hepatocyte growth factor is a multifunctional protein 
that was first found as a potent mitogenic protein for 
mature hepatocytes and later demonstrated its role in cell 
protection, regeneration, tissue survival, and repair. With 
emerging evidence that it protects against key events in 
autoimmune and inflammatory disorders, approaches 
have been made to explore the possibility of its thera-
peutic use against diseases such as autoimmune neuro-
inflammation, rheumatoid arthritis, and asthma [8–10]. 
However, as for ocular diseases, such agents of large mol-
ecules can hardly penetrate the ocular tissues and barri-
ers to taking effects. In this regard, small peptides derived 
from key active parts of certain functional proteins display 
promising potential to target ocular disorders [6, 11, 12].
Previously, we have identified an 11-amino-acid pep-
tide, H-RN (RNPRGEEGGPW), from the Kringle 1 
domain of HGF using biological information technol-
ogy and have studied its inhibitory effect in uveitis and 
neovascularization [13, 14]. In fact, among ocular sur-
face diseases, keratitis has a much higher incidence rate 
than uveitis. Besides, the cells, pathogenic factors, and 
mechanisms involved in the two diseases are not the 
same. Whether H-RN exhibits a protective effect on cor-
neal inflammation was not explored yet. Besides, previ-
ously, only LPS was used in the experiments, and it was 
still unknown whether H-RN had an effect on poly(I:C)-
induced inflammation, which was important in studying 
virus-related inflammation. To investigate H-RN’s effect 
on keratitis, the corneal fibroblasts, the primary resi-
dent cells of the cornea and the most vulnerable cells in 
keratitis, were studied. Not only LPS, a surrogate for bac-
teria but also poly(I:C), a synthetic analog of viral dou-
ble-stranded RNA, were applied for the first time in our 
research to see whether H-RN interferes with the virus- 
or bacteria-related inflammation. Also, an animal model 
of LPS-induced corneal inflammation was conducted 
and administrated with H-RN to study its effect in vivo. 
Moreover, the possible mechanisms concerning inflam-
mation signaling were also investigated.
Methods
Peptide synthesis
Peptide H-RN (RNPRGEEGGPW) and a scrambled con-
trol peptide H-GP (GPERWRGPNGE) were synthesized 
by China Peptides Co., Ltd (Shanghai, China) using the 
high-efficiency solid-phase method. The final product 
reached purity over 98% that was characterized by ana-
lytical high-performance liquid chromatography and 
mass spectrometry. All the peptides were kept in −30 °C 
and dissolved in the medium before the experiments.
Cell culture and induction of inflammation in corneal 
fibroblasts—in vitro model
Human corneal fibroblasts (Catalog #6520) were 
obtained from ScienCell company (ScienCell, Carlsbad, 
CA, USA). Cells were cultured in Fibroblast Medium 
containing 2% FBS, 1% fibroblast growth supplement 
(FGS), and 1% penicillin/streptomycin solution as rec-
ommended by ScienCell. Corneal fibroblasts were cul-
tured at 37  °C in 5% humidified CO2. Cells between 
passages 4–8 were used in the experiments. LPS from 
Escherichia coli (Sigma-Aldrich, Inc., St. Louis, MO, 
USA) (10 μg ml−1) and poly(I:C) (Invivogen, San Diego, 
California, USA) (10  μg  ml−1) were used to induce an 
inflammatory reaction in corneal fibroblasts. Different 
concentrations of H-RN (10 μM, 50 μM, 100 μM), H-GP 
(100  μM), and dexamethasone(DEX) (100  μM) (Shang-
hai General Motors Pharmaceutical Industry Com-
pany Limited, China) were added to different groups as 
interventions.
Induction of keratitis in rats—in vivo model
All experiments were consistent with the ARVO State-
ment for the Use of Animals in Ophthalmic and Vision 
Research. Male Wistar rats (200–240  g) were procured 
from Shanghai Laboratory Animal Center, Chinese Acad-
emy of Sciences and were maintained in a 12 h light/12 h 
dark cycle. Food and water were supplied ad libitum. The 
rats were divided into appropriate experimental groups 
by complete randomization. Keratitis was induced by 
injecting LPS into the corneal stroma of the rats as 
described before [2, 15]. Briefly, after anesthetization 
of the rats, a tunnel to the central stroma of the cornea 
was created by a 33-gauge needle (Hamilton Co., Reno, 
NV, USA). Then another 33-gauge needle attached to a 
5-μl syringe was used to inject 10 μg LPS (diluted in 5 μl 
saline) into the stroma through the tunnel. Rats in the 
control group only received a 5-μl saline stromal injec-
tion. LPS group was subconjunctivally injected with 20 μl 
saline, while peptide groups received a subconjunctival 
injection of 20 μl saline containing 10, 20 or 50 μg H-RN, 
or 50 μg H-GP separately. Besides, we also administered 
eye drops (20 μl) containing 10, 20, or 50 μg peptides to 
the LPS-induced rats every 4 h for 24 h. DEX was used as 
the drug control.
ELISA assay
IL-6, MCP-1, and IFN-γ of corneal fibroblasts (n  =  7) 
and rat corneas (n = 7P) were measured by ELISA assay. 
Cell supernatants of different groups were collected, cen-
trifuged, and stored at −80 °C. The rat corneas were iso-
lated carefully and homogenized in 100-μl sterile PBS, 
which were then centrifuged at 15,000 rpm for 20 min at 
4 °C. Finally, the supernatants were collected and stored 
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at −80  °C. Both samples from cells and corneas were 
quantified by different ELISA Kits (R&D Systems, Minne-
apolis, MN, USA) according to the manufacturer’s direc-
tions. All measurements were performed in triplicate.
RT‑PCR analysis
RT-PCR was performed to determine the mRNA level 
of IL-6, MCP-1, IFN-γ, and ICAM-1, both in the cells 
(n = 7) and the corneas (n = 7). The total RNA of cor-
neal fibroblasts and rat cornea were extracted using Tri-
zol reagent (Invitrogen, Carlsbad, CA, USA) and detected 
by performing RT-PCR on in a ViiA 7 Detection System 
(Applied Biosystems, Foster City, CA, USA). The amount 
of IL-6, MCP-1, IFN-γ, or ICAM-1 mRNA was normal-
ized by that of GAPDH mRNA and is presented in arbi-
trary units (1 unit corresponds to the value for cells in 
control group).
The primer used were as follows:
human IL-6:(forward) 5′- TTCGGTCCAGTTGCCTT 
CT-3′ and (reverse) 5′-GGTGAGTGGCTGTCTGTG 
TG-3′; human MCP-1: (forward) 5′-ATCAATGCCCCAG 
TCACCT-3′ and (reverse) 5′-TCCTGAACCCACTTCTG 
CTT-3′; human IFN-γ: (forward) 5′-GAGTGTGGAGAC 
CATCAAGGA-3′ and (reverse) 5′-GTATTGCTTTGCG 
TTGGACA-3′; human ICAM-1 (forward) 5′-TCACCTAT 
GGCAACGACTCC-3′ and (reverse) 5′-CAGTGTCTCC 
TGGCTCTGGT-3′; rat IL-6: (forward) 5′-AGTTGCCT 
TCTTGGGACTGA-3′ and (reverse) 5′-ACTGGTCTGT 
TGTGGGTGGT-3′; rat MCP-1(forward) 5′-TCACCTGC 
TGCTACTCATTCA-3′ and (reverse) 5′-CCATTCCTTA 
TTGGGGTCAG-3′.
Immunofluorescence detection
For detection of the p65 subunit of NF-κB and the 
expression of ICAM-1 in the cells, immunofluorescence 
was performed (n = 5). Corneal fibroblasts were seeded 
on coverslips cultured in fibroblast medium containing 
2% FBS and were changed to serum-free medium over-
night when the cells reached 80–90% confluence. Then 
the cultured corneal fibroblasts were stimulated with LPS 
(10 μg ml−1) or poly(I:C) (10 μg ml−1) for 1 h to detect 
NF-κB p65 and 24  h to detect ICAM-1. At the same 
time, cells were incubated with or without H-RN (10, 
50, 100 μM), or H-GP (100 μM). After being washed, the 
cells were fixed with methanol: acetone (1:1), permeabi-
lized by 0.1% Triton X-100 for 10 min, and blocked with 
PBS containing 2% bovine serum albumin for 30  min. 
Then the cells were incubated with primary antibody 
against NF-κB p65 (rabbit monoclonal antibodies to 
NF-κB p65, 1:1000, Cell Signaling Technology, Beverly, 
MA, USA) and ICAM-1 (mouse monoclonal antibodies 
to ICAM-1, 1:500, R&D, Minneapolis, MN, USA) over-
night at 4 °C. The secondary antibodies (Alexa Fluor 555, 
1:500, Molecular Probes, Eugene, OR, USA,) against rab-
bit or mouse IgG were incubated with the cells for 1  h. 
The cells were stained with DAPI before being viewed 
and captured with a confocal laser scanning microscope 
(Zeiss LSM510; Carl Zeiss, Thornwood, NY, USA).
Western blot analysis
Cells (n  =  5) were pretreated with different concentra-
tions of H-RN for 30  min and then incubated with LPS 
or poly(I:C) (both 10  μg  ml−1) for 1.5  h (for NF-κB and 
MAPKs) or 24  h (for ICAM-1). After that, cells were 
washed in ice-cold PBS, collected, lysed, and centrifuged. 
Protein concentrations were determined by a Bradford 
protein assay (Bio-Rad, Munich, Germany). The lysates of 
the samples were loaded and separated by SDS-PAGE and 
then electrophoretically transferred to polyvinylidene dif-
luoride membranes. The membranes were blocked with 
5% BSA and incubated with primary antibodies over-
night at 4 °C, which included ICAM-1 (R&D, Minneapo-
lis, MN, USA), NF-κB p65, p-NF-κB p65, IκBα, p-IκBα, 
ERK, p-ERK, JNK, p-JNK, p38, and p-p38 (Cell Signaling 
Technology, Beverly, MA, USA). After washing, the mem-
branes were further detected with secondary anti-rabbit 
or anti-mouse antibodies (Santa Cruz, CA, USA). Images 
of the bands were obtained using Amersham Imager 600 
system (GE Healthcare Bio-Sciences AB, Uppsala, Swe-
den). Analyses of the relative protein levels were evalu-
ated by Image J software (NIH). The experiments were 
repeated at least three times to ensure reproducibility.
Clinical evaluation
Examination with a biomicroscope on a masked basis 
was performed on all the rats 24  h after LPS stimula-
tion. The severity of the stromal keratitis was graded in 
a blinded fashion with a scoring system described pre-
viously [16]: 0.0 =  Normal; 0.5–0.9 =  Mild edema, not 
diffuse, no haze; 1.0–1.9  =  Significant edema, slight 
haze, iris clearly visible; 2.0–2.9 = Gross edema, stromal 
swelling, cloudy, diffuse, can see anterior chamber, iris 
visible; 3.0 = Severe stromal edema, very cloudy, cannot 
see anterior chamber, pupillary border no longer distinct; 
4.0  =  Opaque cornea, anterior chamber structure not 
visible.
Histopathological examination
Corneas were histologically studied to evaluate the effect 
of H-RN on stromal keratitis. Eyes were removed and 
fixed in 4% paraformaldehyde overnight at room tempera-
ture. Sagittal serial sections were taken and stained using 
hematoxylin and eosin (H&E). The number of infiltrated 
cells in the cornea per field was evaluated under light 
microscopy in a masked fashion and manually counted by 
two independent researchers of four random fields.
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Safety assessment
To evaluate the irritation and ocular safety of 
H-RN solutions, both cell examination and in  vivo 
assessment were developed. 3-(4,5-dimethylthia-
zol-2-yl)-5-(3-carboxymethoxypehenol)-2-(4-sul-
phophenyl)-2H-tetrazolium (MTS) method was used to 
determine the viability of cells. After incubation with dif-
ferent concentration of H-RN (10, 50, 100, 200  μM) for 
24  h, corneal fibroblasts were treated with 20  ml of the 
MTS reagent (Promega Corporation, Madison, USA) for 
3 h at 37 °C and then a microtiter plate reader (Bio-Rad, 
Model 680, Hercules, CA, USA) was used to measure the 
optical density. Moreover, the possible toxicity was also 
accessed everyday by biomicroscope. One week after rats 
received a subconjunctival injection of 20 μl saline con-
taining 100 μg H-RN, histopathological examination, and 
transmission electron microscope tests were performed.
Statistical analysis
Results are expressed as mean ± SD and were evaluated 
by analysis of variance (ANOVA) followed by Bonferro-
ni’s post hoc test using the SPSS 16.0 software. In cases 
of nonparametric data distribution, the Kruskal–Wal-
lis test was performed followed by Mann–Whitney U 
test. A p value less than 0.05 was considered statistically 
significant.
Materials
Peptide H-RN (RNPRGEEGGPW) and a scrambled 
control peptide H-GP (GPERWRGPNGE) were syn-
thesized by China Peptides Co., Ltd (Shanghai, China). 
Human corneal fibroblasts (Catalog #6520) and Fibro-
blast Medium were obtained from ScienCell company 
(Carlsbad, CA, USA). LPS from Escherichia coli was 
bought from Sigma-Aldrich Inc (St. Louis, MO, USA), 
poly(I:C) was from Invivogen (San Diego, California, 
USA) and dexamethasone (DEX) was from Shanghai 
General Motors Pharmaceutical Industry Company Lim-
ited (Shanghai, China). ELISA Kits and primary antibody 
against ICAM-1 were from R&D (Minneapolis, MN, 
USA). Trizol reagent was from Invitrogen (Carlsbad, CA, 
USA). RT-PCR was performed with a ViiA 7 Detection 
System (Applied Biosystems, Foster City, CA, USA). Pri-
mary antibodies against NF-κB p65, p-NF-κB p65, IκBα, 
p-IκBα, ERK, p-ERK, JNK, p-JNK, p38, and p-p38 were 
obtained from Cell Signaling Technology (Beverly, MA, 
USA). Alexa Fluor 555 secondary antibodies were bought 
from Molecular Probes (Eugene, OR, USA,). Secondary 
anti-rabbit or anti-mouse antibodies used in western blot 
were from Santa Cruz (CA, USA). Immunofluorescence 
detection was performed with a confocal laser scanning 
microscope (Zeiss LSM510; Carl Zeiss, Thornwood, NY, 
USA). Images of the bands were obtained using Amer-
sham Imager 600 system (GE Healthcare Bio-Sciences 
AB, Uppsala, Sweden). Analyses of the relative protein 
levels were evaluated by Image J software (NIH). MTS 
reagent was obtained from Promega Corporation (Madi-
son, USA) and MTS assay was determined with a micro-
titer plate reader (Bio-Rad, Model 680, Hercules, CA, 
USA).
Results
Inhibition of IL‑6, MCP‑1, and IFN‑γ from corneal fibroblasts 
induced by LPS or poly(I:C)
Corneal fibroblasts exposed to LPS or poly(I:C) were 
treated with or without H-RN. The inflammatory cytokines 
including IL-6, MCP-1, and IFN-γ were markedly released 
from corneal fibroblasts. We examined the mRNA and 
protein level of the above cytokines using RT- PCR and 
ELISA methods. As is shown in Fig. 1, LPS induced IL-6 
and MCP-1 increases, which was significantly reduced 
by treatment with H-RN and DEX not only at the mRNA 
(Fig. 1a–d) but also the protein level (Fig. 1e–h). Poly(I:C) 
induced IL-6 and IFN-γ increases and was also remarkably 
inhibited by H-RN and DEX. H-GP had no effect on cor-
neal fibroblasts in the above experiments.
Suppression of the mRNA and surface expression 
of ICAM‑1 in corneal fibroblasts
We performed RT- PCR, immunofluorescence, and 
Western blot to determine the effect of H-RN on the 
ICAM-1, one of the key adhesion molecules involved 
in inflammation. As is shown in Fig. 2, the fluorescence 
intensity (Fig. 2a, b), the band abundance (Fig. 2c–f), and 
the mRNA relative level (Fig. 2g, h) of ICAM-1 were obvi-
ously elevated after stimulation with LPS or Poly(I:C). 
Incubation with H-RN resulted in the significant sup-
pression of ICAM-1 in a dose-dependent manner.
Attenuation of clinical manifestation and reduction 
of clinical score
After injection of LPS for 24 h, a distinctive inflammatory 
response was observed in rat corneas. In the LPS group, 
rats showed severe corneal edema, opacity, and swelling 
with a significantly increased clinical score compared to 
normal rats (Fig. 3). In the H-RN treated group, all those 
symptoms were relieved greatly, especially in the subcon-
junctival injection groups. The clinical score was mark-
edly reduced by subconjunctival injection or eye drops of 
H-RN. In the subconjunctival injection group, the inhibi-
tion effect of H-RN was more significant, and the clinical 
score was lower than the topical administration group. In 
contrast, the scrambled peptide, PAPsc, had no effect on 
corneal inflammation.
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Suppression of histopathological disorders of the corneal 
tissue
Furthermore, we observed the histological manifes-
tations between different groups. As shown in Fig.  4, 
LPS disrupted the structure of the normal cornea, leav-
ing the tissue obviously thickened, swollen, and the 
cells arranged in disorder with an infiltration of large 
amounts of inflammatory cells. The pathological results 
were consistent with clinical features. In H-RN- and 
DEX-treated rats, especially those who received a sub-
conjunctival injection, the disorders of the corneal tis-
sue were significantly ameliorated with fewer infiltrated 
cells. There is no difference between the PAPsc and LPS 
groups.
Reduction of mRNA and protein expression 
of inflammatory cytokines in rat corneas
We also conducted RT-PCR and ELISA to identify the 
level of IL-6 and MCP-1 in rat corneas. By the results 
from corneal fibroblasts, both the mRNA transcrip-
tion (Fig. 5a) and protein expression (Fig. 5b) of the two 
cytokines were significantly inhibited by H-RN compared 
with the control group.
Effects of the LPS‑ or poly(I:C)‑induced phosphorylation 
of IκBα, p65, and p65 translocation in the corneal 
fibroblasts
NF-κB is a crucial nuclear transcription factor involved 
in inflammation and immune diseases. To clarify how 
H-RN affected the NF-κB signaling pathway during cor-
neal inflammation, we detected p65 translocation, phos-
phorylation of IκBα, and p65 in corneal fibroblasts. The 
immunofluorescence of reduced translocation of p65 to 
the nucleus proved that NF-κB activation was inhibited 
by H-RN either in LPS or poly(I:C) treated corneal fibro-
blasts (Fig. 6). The protein determination by Western blot 
found that phosphorylation of IκBα and p65 were both 
significantly increased by induction of LPS as well as 
poly(I:C), but were noticeably decreased after the inter-
vention of H-RN (Fig. 7).
Inhibition of MAPK signaling pathway activated by LPS 
and poly(I:C)
Mitogen-activated protein kinases (MAPKs), includ-
ing p38, JNK, and ERK, contribute to a series of physi-
ological and pathological processes, such as synthesis of 
inflammatory mediators. In this study, we assessed the 
expression of the three participants of MAPKs in LPS- 
or poly(I:C)-induced corneal fibroblasts with or with-
out H-RN intervention. Figure  8 shows a significantly 
higher expression of phosphorylated p38, JNK, and ERK 
after incubation with LPS or poly(I:C), which means the 
activation of MAPKs. However, by treating H-RN, the 
phosphorylation of all MAPKs were suppressed with 
statistical significance. This demonstrates that H-RN 
markedly inhibited the activation of MAPK signaling in 
corneal fibroblasts not only triggered by LPS but also by 
poly(I:C).
Fig. 1 Effect of H-RN on the production of IL-6, MCP-1 and IFN-γ in corneal fibroblasts. Cells were stimulated by LPS (10 μg ml−1) or poly(I:C) 
(10 μg ml−1) and incubated with H-RN (10, 50, 100 μM), H-GP (100 μM), and DEX (100 μM) for 6 h (for RT-PCR) or 24 h (for ELISA). The mRNA (a–d) 
and protein (e–h) level of IL-6, MCP-1, and IFN-γ were analyzed by RT-PCR and ELISA. Data are expressed as mean ± SD. #p < 0.05 compared with 
control group; *p < 0.05 compared with LPS or poly(I:C) group; DEX, dexamethasone
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Safety of H‑RN in corneal fibroblasts and rat eyes
MTS assay showed that incubation with H-RN (10, 50, 
100, 200 μM) had no influence on the viability of corneal 
fibroblasts (Fig. 9a). Moreover, we explored the safety of 
H-RN by performing biomicroscope, histopathological 
examination, and Transmission Electron Microscope on 
the rats and the corneas. No sign of ocular abnormality 
or cell toxicity was detected in any of the assays (Fig. 9b–
d), which demonstrated that H-RN displayed non-toxic-
ity to the cornea.
Discussion
In keratitis, inflammation often lasts and relapses long 
after the microbes were eliminated, causing great harm 
to the structure and function of the cornea. Although 
bacteria and virus could be killed or limited by antibi-
otics, the immune system, once activated, won’t stop 
quickly or immediately and has to be re-regulated by 
anti-inflammatory drugs due to pathogen products such 
as LPS and poly(I:C) [17, 18]. This is the most challeng-
ing difficulty and troublesome part of the management of 
(See figure on previous page.) 
Fig. 2 Suppression by H-RN of mRNA and surface expression of ICAM-1 in corneal fibroblasts. Cells were stimulated by LPS (10 μg ml−1) or poly(I:C) 
(10 μg ml−1) and incubated with or without peptides. The expression of ICAM-1 was measured by immunofluorescence (a, b), Western blot (c–f), and 
RT-PCR (g, h). Data are expressed as mean ± SD. #p < 0.05 compared with control group; * p < 0.05 compared with LPS or poly(I:C) group. Nucleus 
(DAPI, blue), ICAM (in red)
Fig. 3 Attenuation of clinical manifestation (a) and clinical score (b) by H-RN in LPS-induced keratitis in rats. Rats except those in control group 
(PBS injection) were injected with LPS (10 μg diluted in 5-μl saline) into the corneal stroma and received subconjunctival injection or eye drops of 
H-RN or H-GP, DEX. Eyes were examined and scored 24 h later. Data are expressed as mean ± SD. #p < 0.05 compared with control group; *p < 0.05 
compared with LPS group; DEX, dexamethasone
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keratitis. Among the most commonly used anti-inflam-
matory drugs, corticoids are preferred, but their pro-
found side-effects (i.e. cataract, high intraocular pressure, 
difficulty in healing, etc.) have become a major concern 
[5, 19]. An ideal drug should display both desired effi-
ciency and satisfactory safety.
Theoretically, endogenous human proteins are bet-
ter tolerated with much less irritation and toxicity to the 
host, but the large molecular weight and high cost have 
limited their use in ocular disease. Advantages of small 
peptides are obvious over proteins as small peptides have 
lower toxicity and immunology, higher penetration, and 
lower cost [6, 20]. Also, peptides derived from human 
endogenous proteins exert potential biofunctions from 
the original protein as well as unexplored activities due 
to the sequence and structure. Therefore, we focus on the 
screening and development of such peptide agents from 
human endogenous proteins with certain bioactivities to 
target ocular diseases.
H-RN is a 1254.34-Da peptide (sequence RNPR-
GEEGGPW), which we identified with biological infor-
mation technology from human hepatocyte growth 
factor (HGF), a protein demonstrated to regulate auto-
immune and inflammatory diseases [8–10]. Here, in this 
study, we prove for the first time that H-RN effectively 
attenuated LPS- and poly(I:C)-induced corneal inflam-
mation in vivo and in vitro and its effects were mediated 
by suppressing the NF-κB and MAPK/p38/JNK/ERK 
pathways. The effect is in a dose- and sequence-depend-
ent manner.
Both LPS, surrogate for bacteria, and poly(I:C), an 
analog of the virus, were used in our study. It is accepted 
that the two agents are strong stimuli to the immune sys-
tem and activate Toll-like receptors 3 (TLR3) and TLR4 
[21, 22]. TLRs are major pattern receptors that recognize 
multiple microbial products and mediate inflammatory 
reactions through producing various chemokines and 
cytokines to participate in the clearance of the microbes 
Fig. 4 Effect of H-RN on histological disorders and cell infiltration in the cornea. Eyeballs were collected 24 h after LPS injection. a Histological 
observation b number of infiltrated inflammatory cells. Original magnification (A–J) ×100 Data are expressed as mean ± SD. #p < 0.05 compared 
with control group; *p < 0.05 compared with LPS group; DEX dexamethasone
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and to defend the host. Meanwhile, the enduring pro-
cess breaks the homeostasis and destroys the physi-
ological structure essential to the normal function [23, 
24]. Among the mediators involved in the TLRs trans-
duction, IL-6, MCP-1, and IFN-γ play crucial roles [3, 
25, 26]. When corneal fibroblasts were infected with 
bacteria or virus and activated by the stimulation, those 
cytokines were released rapidly as TLRs respond to the 
microbial components. We quantified the mRNA and 
protein level of IL-6, MCP-1 and IFN-γ after LPS or 
poly(I:C) stimulation, and found that peptide H-RN 
effectively attenuated the increased expressions of those 
mediators. Furthermore, we demonstrated with dif-
ferent means that the expression of ICAM-1 triggered 
by LPS or poly(I:C) was significantly inhibited by treat-
ment of H-RN, which, together with the above results, 
suggested that H-RN could limit the degree of inflam-
matory reaction by suppressing the principle cytokines, 
chemokines, and adhesion molecules. One of the main 
effects that those mediators produce is the recruitment 
and infiltration of various leukocytes to the cornea. 
Those infiltrated inflammatory cells, together with acti-
vated corneal fibroblasts, release cytotoxic agents and 
proteases to aggressively clear the pathogens. However, 
at the same time, the process unavoidably causes exten-
sive damage to the cornea by degrading the stromal col-
lagen and destroying corneal integrity and clarity. It has 
been implied that depletion of leukocytes or suppres-
sion of adhesion molecules resulted in relieved corneal 
inflammation and less destruction [2]. So, next, we veri-
fied H-RN’s in  vivo efficiency in LPS-induced keratitis 
and proved that H-RN effectively attenuated the clinical 
symptoms in rats and greatly decreased the infiltration of 
inflammatory cells and abnormalities in the cornea. Also, 
IL-6, MCP-1, and IFN-γ were also significantly reduced 
in rat corneas after H-RN injection or topical application. 
The in vivo results are by and further validated findings 
of in vitro assays. Moreover, previously we have demon-
strated HRN’s effectiveness in inhibiting corneal neovas-
cularization [27]. Since inflammatory disease are often 
accompanied by angiogenesis, it is highly believed that 
HRN is protective to corneal inflammation not only due 
Fig. 5 Effect of H-RN on mRNA and protein level of inflammatory cytokines in rat corneas. The mRNA and protein level of IL-6 and MCP-1 of rat 
corneas were analyzed by RT-PCR (a) and ELISA (b). Data are expressed as mean ± SD. #p < 0.05 compared with control group; *p < 0.05 compared 
with LPS group; DEX dexamethasone
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to its anti-inflammation role but also its anti-angiogenic 
activity.
To illuminate the mechanisms of H-RN’s effect on 
keratitis, we investigated the possible signaling pathways 
involved in inflammation. It is recognized that NF-κB 
and MAPK signals are principle pathways of the cornea 
to regulate the cytokines and cells to participate in the 
inflammatory process [25, 28, 29]. Insults such as LPS 
and poly(I:C) are strong activators to TLRs, which then 
trigger the NF-κB and MAPK pathways to defense the 
host. NF-κB is believed to be a crucial initiative factor 
regulating inflammatory gene expression. It is activated 
by degradation of IκBα, the inhibitor protein of NF-κB, 
and then translocates from cytoplasm to the nucleus to 
promote target genes of the immune system [30]. MAPKs 
also play an important role in cellular activities including 
inflammation, innate immunity, and apoptosis. They are 
a family of serine/threonine protein kinases mainly con-
sisting of JNK, p38, and ERK. It has been demonstrated 
that activation of TAK1, an upper member of TLR sign-
aling, triggers both the NF-κB and the MAPK pathway 
[31]. In regards to this, we tested the expression of the 
main proteins involved in the two pathways to clarify 
the mechanism underlying H-RN’s anti-inflammatory 
property in keratitis. As we proved in this study, H-RN 
effectively inhibited the activation of NF-κB and MAPK 
signaling by reduction of p65 translocation and suppres-
sion of phosphorylation of IκBα, p65, ERK, p38, and JNK, 
Fig. 6 Reduction of translocation of p65 subunit of NF-κB by H-RN in corneal fibroblasts induced by LPS or poly(I:C). Translocation of p65 subunit of 
NF-κB was observed by immunofluorescence (a). The percentage of the number of translocated cells (b) was calculated by counting the number of 
cells with nuclear translocation in a masked fashion. Data are expressed as mean ± SD. #p < 0.05 compared with control group; *p < 0.05 compared 
with LPS or poly(I:C) group. Nucleus (DAPI, blue), ICAM (in red)
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which explains the protective role of H-RN in keratitis. 
Meanwhile, because the NF-κB and MAPK pathways 
share some of the top regulators and cross-talks on the 
TLR-signaling pathway, it is possible that H-RN affected 
certain such shared signals, which needs to be studied 
further and is under active investigation in our next work.
The safety of the drug in ocular tissues is a major con-
sideration. We conducted safety evaluations with biomi-
croscopes, histological observations, and transmission 
electron microscopes after subconjunctival injection 
of H-RN, as well as cell viability measures on corneal 
fibroblasts. No sign of clinical irritation or damage in 
the ultrastructure was shown. Also, no difference in cell 
viability was noticed in corneal fibroblasts incubated 
with H-RN. From what we observed in the study, H-RN 
is non-toxic to the eye, which is consistent with the fact 
that it is an endogenous derivation. Certainly, more 
examinations remain to be finished in the future to com-
prehensively verify H-RN’s effects other than its anti-
inflammatory property.
Fig. 7 Inhibition of activation of NF-κB signaling pathway by H-RN in corneal fibroblasts induced by LPS or poly(I:C). The effect of H-RN on phos-
phorylation of IκBα and p65 in corneal fibroblasts induced by LPS (a, c, e) or poly(I:C) (b, d, f) were detected by western blots. Data are expressed as 
mean ± SD. #p < 0.05 compared with control group; *p < 0.05 compared with LPS or poly(I:C) group
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Fig. 8 Suppression of MAPK signaling pathway by H-RN in corneal fibroblasts stimulated by LPS or poly(I:C). Expressions of the three participants 
(p38, JNK, and ERK) of MAPKs in corneal fibroblasts with or without H-RN intervention after stimulation with LPS (a, c, e, g) or poly(I:C) (b, d, f, h) 
were accessed by Western blots. Data are expressed as mean ± SD. #p < 0.05 compared with control group; *p < 0.05 compared with LPS or poly(I:C) 
group
Page 13 of 14Zhu et al. J Transl Med  (2017) 15:20 
Since H-RN is derived from endogenous protein and 
has only 11 amino acids, it is much more cost-effective 
and has better penetration ability than large proteins, 
as well as lower irritation than chemical drugs. But the 
half-life may be short with such a small peptide and 
the penetration of H-RN in different ocular tissues still 
needs to be proved, which are limitations of the pre-
sent study. Also, there is no mature animal model other 
than LPS-induced keratitis available to further explore 
the effect of H-RN on corneal inflammation. Virus-
stimulated animal keratitis does not fit in our study as 
H-RN is not an anti-virus agent and it mainly targets 
the immune response during inflammation rather than 
killing the microbes. For this reason, the in vivo model 
of LPS-induced keratitis was chosen in our study. It 
should be noted that subconjunctival injection showed 
better efficiency than topical drops of H-RN, indicat-
ing that a longer-acting time may increase the benefits 
of this small peptide. Although the present data did not 
show a better effect of H-RN as compared with DEX, 
the potential of H-RN will be further developed as it 
is now only a pure peptide and not yet modified. It is 
suggested that with a proper modification method and 
an improved delivery system, the efficiency of the pep-
tide drug will be strengthened [32, 33].
Conclusion
In conclusion, we have shown that the novel peptide 
H-RN, which we derived from HGF, effectively attenu-
ated keratitis in  vivo and in  vitro through blocking the 
NF-κB and MAPK signaling pathways. Therefore, H-RN 
exhibits great potential as a promising and safe agent in 
the future in treating keratitis.
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